Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

CTX-10726

Other · developed by Compass Therapeutics

Phase 1 Most advanced trial

CMPS Developer

1 Registered trials

What is CTX-10726?

CTX-10726 is an investigational drug studied in Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC), Endometrial Cancer.

At a glance

Drug type: Other
Therapy area: Oncology
Developer: Compass Therapeutics (CMPS, CMPX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07419841	Phase 1	Gastroesophageal Cancer (GC)	Recruiting	CMPS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Endometrial CancerGastroesophageal Cancer (GC)Hepatocellular Carcinoma (HCC)Renal Cell Carcinoma (RCC)

More from Compass Therapeutics

COMP360 psilocybin Phase 2/3 CTX-471 Phase 1/2 CTX-8371 Phase 1 Psilocybin Phase 3 Tovecimig Phase 2/3

Sources

ClinicalTrials.gov NCT07419841

Updated Oct 3, 2026. Something wrong or missing? Report it on the CMPS page.

Follow CMPS, the company behind CTX-10726

See CMPS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CMPS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z